{"text": "$bmy what happened here"}
{"text": "another tactical victory for $mrk: getting fda review of keytruda-chemo combo for lung cancer. $bmy #jpm17 URL"}
{"text": "a long opportunity in novo nordisk URL $mrk $abbv $bmy $sny $azn $pfe $gsk $lly $jnj $nvo"}
{"text": "people panic selling $bmy down 3.5% in after hours. think they're gonna regret that this time."}
{"text": "rt AT_USER #algorithms $mrk gain $bmy pain (pair trade) - #merck up 3.8 #bristol down 3.8 - not a coincidence  $ibb $xbi $xlv #jpm17"}
{"text": "rt AT_USER $bmy immuno-oncology key catalysts in near term #jpm17 URL"}
{"text": "$bmy at $jpm transcript: URL"}
{"text": "#options #maxpain chart for $bmy. free stock station app URL #itunes URL"}
{"text": "#algorithms $mrk gain $bmy pain (pair trade) - #merck up 3.8 #bristol down 3.8 - not a coincidence  $ibb $xbi $xlv #jpm17"}
{"text": "$bmy down over 4% after hours, guidance at jpm conference."}
{"text": "$bmy getting hit after hours\u00a1\u00ad channel low / 50ma set-up well for a roro long. URL"}
{"text": "$bmy #options oi chart. free stock station app URL #itunes URL"}
{"text": "AT_USER still don't get why $bmy is getting hit so hard after hours. this news should have been priced in. obviously it was coming."}
{"text": "AT_USER what happened to $bmy in ah?"}
{"text": "AT_USER $bmy gettin slapped in ah"}
{"text": "after hours gainers / losers $ichr $akao $arwr $mrk $kopn $nvdq $wg $pe $bmy $jnpr $cur URL"}
{"text": "btw, estimated #earnings per share for $bmy is $0.79 it's 1.32% of the current price URL"}
{"text": "AT_USER any news for $bmy in the after hours- down over 2%"}
{"text": "rt AT_USER #jpm17 $mrk files keytruda/chemo combo data from kn-021 study with fda - who saw that coming? $bmy"}
{"text": "rt AT_USER $bmy immuno-oncology key catalysts in near term #jpm17 URL"}
{"text": "$bmy URL cup &amp; handle. rising 50 dma. time to make a move hopefully. keep a stop"}
{"text": "#jpm17 $mrk files keytruda/chemo combo data from kn-021 study with fda - who saw that coming? $bmy"}
{"text": "news on $bmy?? cc AT_USER AT_USER AT_USER AT_USER AT_USER AT_USER AT_USER"}
{"text": "rt AT_USER $bmy thinks it has a best-in-class ido inhibitor. data on its profile to be released later last year. #jpm17"}
{"text": "rt AT_USER $bmy immuno-oncology key catalysts in near term #jpm17 URL"}
{"text": "$bmy getting slaughtered in after hours. not looking good for the trade"}
{"text": "AT_USER AT_USER AT_USER anyone know if something going w $bmy? ah very odd sell off or manipulation"}
{"text": "rt AT_USER $bmy immuno-oncology key catalysts in near term #jpm17 URL"}
{"text": "rt AT_USER $bmy immuno-oncology key catalysts in near term #jpm17 URL"}
{"text": "rt AT_USER $bmy immuno-oncology key catalysts in near term #jpm17 URL"}
{"text": "AT_USER this is very strange ah action for $bmy"}
{"text": "block summary: [ $bmy ] : price[$60.22] : day close[$59.98] : volume[540,000] : from[15:23:22] : to[15:23:22] #bmy"}
{"text": "block summary: [2017-01-10] : [ $bmy ] : total volume[540,000] : cumulative avg[$60.22] : day close[$59.98] #bmy"}
{"text": "$bmy getting hit hard ah"}
{"text": "$imuc best guess $bmy $mrk agreed to run combo study with ict-107"}
{"text": "rt AT_USER $bmy opdivo growth seems to be hanging in there even after the esmo fiasco with keytruda #jpm17 URL"}
{"text": "$bmy pullback time! closed below 60 after a nice bounce, not good!"}
{"text": "AT_USER the health care sector kept the nasdaq above water, but $bmy didnt do much to contribute"}
{"text": "$bmy seems to be having a hard time crossing and staying above the 60 mark"}
{"text": "salphatrending: bristol-myers squibb (bmy) presents at jpmorgan healthcare conference (transcript) URL $bmy"}
{"text": "bristol-myers squibb (bmy) presents at jpmorgan healthcare conference (transcript) URL $bmy"}
{"text": "rt AT_USER $bmy immuno-oncology key catalysts in near term #jpm17 URL"}
{"text": "rt AT_USER $bmy immuno-oncology key catalysts in near term #jpm17 URL"}
{"text": "rt AT_USER $bmy immuno-oncology key catalysts in near term #jpm17 URL"}
{"text": "rt AT_USER $bmy thinks it has a best-in-class ido inhibitor. data on its profile to be released later last year. #jpm17"}
{"text": "rt AT_USER $bmy immuno-oncology key catalysts in near term #jpm17 URL"}
{"text": "rt AT_USER $bmy immuno-oncology key catalysts in near term #jpm17 URL"}
{"text": "block trade: $bmy 540,000 shares @ $60.22 [15:23:22] #blocktradealert"}
{"text": "block trade: $bmy 540,000 shares @ $60.22 [15:23:22] #blocktradealert"}
{"text": "block trade: $bmy 540,000 shares @ $60.22 [15:23:22]"}
{"text": "rt AT_USER $bmy immuno-oncology key catalysts in near term #jpm17 URL"}
{"text": "rt AT_USER $bmy immuno-oncology key catalysts in near term #jpm17 URL"}
{"text": "rt AT_USER $bmy more competition for opdivo in lung this year, but expect to transform rapidly to combo therapy. same happened in mela\u00a1\u00ad"}
{"text": "rt AT_USER $bmy immuno-oncology key catalysts in near term #jpm17 URL"}
{"text": "rt AT_USER $bmy focus on right data, medicines &amp; you will get payer support. #jpm17 too early to say what will happen on policy under\u00a1\u00ad"}
{"text": "$bmy still very strong. also, i may add to my $twtr position"}
{"text": "rt AT_USER $bmy thinks it has a best-in-class ido inhibitor. data on its profile to be released later last year. #jpm17"}
{"text": "#bristolmyerssquibb brief-bristol-myers sees operating expenses flat through 2020. read more: URL $bmy"}
{"text": "#bristolmyerssquibb brief-bristol-myers sees operating expenses flat through 2020. read more: URL $bmy"}
{"text": "rt AT_USER $bmy more competition for opdivo in lung this year, but expect to transform rapidly to combo therapy. same happened in mela\u00a1\u00ad"}
{"text": "rt AT_USER $bmy thinks it has a best-in-class ido inhibitor. data on its profile to be released later last year. #jpm17"}
{"text": "rt AT_USER $bmy seeing pdl-1 testing at about 60-65% which was what they expected. keytruda mostly being used in 50+% expressers. #jpm\u00a1\u00ad"}
{"text": "$bmy next-generation #immunotherapy #oncology URL"}
{"text": "rt AT_USER $bmy more competition for opdivo in lung this year, but expect to transform rapidly to combo therapy. same happened in mela\u00a1\u00ad"}
{"text": "$bmy ceo caforio: have a very strong internal/external io portfolio. some internal programs better than what's available externally #jpm17"}
{"text": "$bmy focus on right data, medicines &amp; you will get payer support. #jpm17 too early to say what will happen on policy under peotus."}
{"text": "rt AT_USER $bmy's cuss thinks their ido inhibitor has potential to be best-in-class #jpm17"}
{"text": "rt AT_USER $bmy thinks it has a best-in-class ido inhibitor. data on its profile to be released later last year. #jpm17"}
{"text": "rt AT_USER $bmy more competition for opdivo in lung this year, but expect to transform rapidly to combo therapy. same happened in mela\u00a1\u00ad"}
{"text": "rt AT_USER $bmy seeing pdl-1 testing at about 60-65% which was what they expected. keytruda mostly being used in 50+% expressers. #jpm\u00a1\u00ad"}
{"text": "$bmy seeing similar reimbursement curves in germany, certain other countries compared w/us. happy w/payer response in italy, spain. #jpm17"}
{"text": "rt AT_USER $bmy seeing pdl-1 testing at about 60-65% which was what they expected. keytruda mostly being used in 50+% expressers. #jpm\u00a1\u00ad"}
{"text": "rt AT_USER $bmy seeing pdl-1 testing at about 60-65% which was what they expected. keytruda mostly being used in 50+% expressers. #jpm\u00a1\u00ad"}
{"text": "$bmy seeing pdl-1 testing at about 60-65% which was what they expected. keytruda mostly being used in 50+% expressers. #jpm17"}
{"text": "rt AT_USER $bmy thinks it has a best-in-class ido inhibitor. data on its profile to be released later last year. #jpm17"}
{"text": "$bmy thinks it has a best-in-class ido inhibitor. data on its profile to be released later last year. #jpm17"}
{"text": "$bmy's cuss thinks their ido inhibitor has potential to be best-in-class #jpm17"}
{"text": "$bmy on poss aca repeal: we didn\u00a1\u00aft really see change in mix of our business with aca \u00a8c don\u00a1\u00aft think we\u00a1\u00afll be particularly impacted #jpm17"}
{"text": "rt AT_USER $bmy immuno-oncology key catalysts in near term #jpm17 URL"}
{"text": "rt AT_USER there is global scope to our business development activity, clearly in immunotherapies-oncology ... and our other areas as\u00a1\u00ad"}
{"text": "rt AT_USER $bmy need to move with speed and agility to remain competitive. #jpm17"}
{"text": "rt AT_USER $bmy more competition for opdivo in lung this year, but expect to transform rapidly to combo therapy. same happened in mela\u00a1\u00ad"}
{"text": "rt AT_USER $bmy obviously do expect to see more competition in 2017, particularly in lung cancer. #jpm17"}
{"text": "rt AT_USER $bmy more competition for opdivo in lung this year, but expect to transform rapidly to combo therapy. same happened in mela\u00a1\u00ad"}
{"text": "$bmy maintain opex flat through 2020 while investing in pipeline. #jpm17"}
{"text": "rt AT_USER $bmy more competition for opdivo in lung this year, but expect to transform rapidly to combo therapy. same happened in mela\u00a1\u00ad"}
{"text": "rt AT_USER $bmy eliquis growth is strong as xarelto growth is in decline, $ptla andexxa approval in 2017 should help both drugs #j\u00a1\u00ad"}
{"text": "$bmy eliquis growth pretty amazing, what a monster $pfe"}
{"text": "rt AT_USER $bmy immuno-oncology key catalysts in near term #jpm17 URL"}
{"text": "rt AT_USER $bmy immuno-oncology key catalysts in near term #jpm17 URL"}
{"text": "rt AT_USER $bmy more competition for opdivo in lung this year, but expect to transform rapidly to combo therapy. same happened in mela\u00a1\u00ad"}
{"text": "$bmy need to move with speed and agility to remain competitive. #jpm17"}
{"text": "rt AT_USER $bmy more competition for opdivo in lung this year, but expect to transform rapidly to combo therapy. same happened in mela\u00a1\u00ad"}
{"text": "rt AT_USER $bmy more competition for opdivo in lung this year, but expect to transform rapidly to combo therapy. same happened in mela\u00a1\u00ad"}
{"text": "35th annual j.p. morgan healthcare conference URL $bmy"}
{"text": "35th annual j.p. morgan healthcare conference URL $bmy"}
{"text": "$bmy immuno-oncology key catalysts in near term #jpm17 URL"}
{"text": "rt AT_USER $bmy more competition for opdivo in lung this year, but expect to transform rapidly to combo therapy. same happened in mela\u00a1\u00ad"}
{"text": "rt AT_USER #jpm17 $bmy looks like preview what to expect in q4 earnings URL"}
{"text": "$bmy more competition for opdivo in lung this year, but expect to transform rapidly to combo therapy. same happened in melanoma. #jpm17"}
